FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2025/12/099338 [Registered on: 17/12/2025] Trial Registered Prospectively
Last Modified On: 17/12/2025
Post Graduate Thesis  Yes 
Type of Trial  Interventional 
Type of Study   Diagnostic 
Study Design  Single Arm Study 
Public Title of Study   A Study to Assess a New Blood Test for Early Detection of Leptospirosis in Patients Attending a Tertiary Care Hospital in Kancheepuram District 
Scientific Title of Study   Clinical Evaluation of a Novel Multiplex PCR Panel (LipL21, LipL32, LipL41) for Leptospirosis Diagnosis in Kancheepuram District 
Trial Acronym  NILL 
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Dr.Farida Fahhima A 
Designation  Postgraduate 
Affiliation  Saveetha Medical College and Hospital 
Address  Department of Community Medicine , third floor, Saveetha medical college and hospital, Poonamallee , Chennai, Kuthambakkam, Tamil Nadu 602105 ,India . Saveetha medical college and hospital, Poonamallee,Chennai,Kuthambakkam, Tamil Nadu 602105, India . Chennai TAMIL NADU 602105 India

Kancheepuram
TAMIL NADU
600040
India 
Phone  9345153967  
Fax    
Email  farida.7fahhima@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  Dr.Nisha B 
Designation  Associate Professor 
Affiliation  Saveetha Medical College and Hospital 
Address  Department of Community Medicine , third floor, Saveetha medical college and hospital, Poonamallee , Chennai, Kuthambakkam, Tamil Nadu 602105 ,India .

Kancheepuram
TAMIL NADU
600040
India 
Phone  9884713773  
Fax    
Email  Nishab.smc@saveetha.com  
 
Details of Contact Person
Public Query
 
Name  Dr.Nisha B 
Designation  Associate Professor 
Affiliation  Saveetha Medical College and Hospital 
Address  Department of Community Medicine, third floor, Saveetha medical college and hospital, Poonamallee , Chennai, Kuthambakkam, Tamil Nadu 602105 ,India.

Kancheepuram
TAMIL NADU
600040
India 
Phone  9884713773  
Fax    
Email  Nishab.smc@saveetha.com  
 
Source of Monetary or Material Support  
NIL 
 
Primary Sponsor  
Name  Farida Fahhima A 
Address  Saveetha medical college and hospital, Poonamallee,Chennai,Kuthambakkam, Tamilnadu 602105 ,India . 
Type of Sponsor  Other [Self] 
 
Details of Secondary Sponsor  
Name  Address 
NOT APPLICABLE  NOT APPLICABLE 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Farida Fahhima A  Saveetha Medical College and Hospital Institutional Ethics Committee  Department of Community Medicine , third floor, Saveetha medical college and hospital, Poonamallee , Chennai, Kuthambakkam, Tamil Nadu 602105 ,India . Chennai TAMIL NADU
Chennai
TAMIL NADU 
9345153967

farida.7fahhima@gmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
SMCH-IEC  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: B968||Other specified bacterial agents as the cause of diseases classified elsewhere,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Intervention  Diagnostic kit "Leptoplex"  Clinical Evaluation of a Novel Multiplex PCR Panel (LipL21, LipL32, LipL41) for Leptospirosis Diagnosis in Kancheepuram District-[LEPTOPLEX] for duration of one year 
Comparator Agent  NIL  NIL 
 
Inclusion Criteria  
Age From  18.00 Year(s)
Age To  65.00 Year(s)
Gender  Both 
Details  Patients of all ages and genders presenting with clinical suspicion of leptospirosis and who can provide informed consent written consent for adults greater or equal to 18 years, and parental or guardian consent for minors. 
 
ExclusionCriteria 
Details  Non-suspected cases and patients unable to provide informed consent. 
 
Method of Generating Random Sequence   Not Applicable 
Method of Concealment   Not Applicable 
Blinding/Masking   Not Applicable 
Primary Outcome  
Outcome  TimePoints 
To assess the sensitivity and specificity of the LEPTOPLEX Multiplex PCR assay for diagnosis of leptospirosis.  Primary outcome (sensitivity and specificity of LEPTOPLEX Multiplex PCR) was assessed at baseline (Day 0), at the time of first clinical presentation, in patients presenting within less than or equal to 7 days of fever onset 
 
Secondary Outcome  
Outcome  TimePoints 
Secondary outcomes included phase-wise diagnostic performance, agreement with MAT, comparison with conventional PCR, turnaround time, gene-wise positivity, and incremental diagnostic yield of the LEPTOPLEX assay.  Secondary outcomes were assessed at baseline (Day 0), during early (Days 1–3) and late acute phases (Days 4–7), and during the convalescent phase (Days 8–14), with final outcome assessment at Day 14–21 or discharge. 
 
Target Sample Size   Total Sample Size="30"
Sample Size from India="30" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   N/A 
Date of First Enrollment (India)   17/01/2026 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="1"
Months="0"
Days="0" 
Recruitment Status of Trial (Global)   Not Applicable 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   N/A 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary  

Leptospirosis is an important re emerging zoonotic disease causing acute febrile illness in tropical regions including Tamil Nadu. Early diagnosis is challenging due to non specific clinical presentation and limited sensitivity of serological tests in the initial phase of illness. Microscopic agglutination test though considered the reference standard requires paired sera and is not useful for early clinical decision making. Polymerase chain reaction based methods can detect leptospiremia in the early acute phase and enable timely treatment.

This study aims to clinically evaluate a novel multiplex PCR panel named LEPTOPLEX targeting LipL21 LipL32 and LipL41 genes for the diagnosis of leptospirosis among clinically suspected adult patients in Kancheepuram district. Adult patients aged 18 to 65 years presenting with acute febrile illness suspected to be leptospirosis will be enrolled. Blood samples will be collected at baseline for LEPTOPLEX testing and compared with conventional PCR and serological testing. Convalescent samples will be collected for serological confirmation.

The primary outcome of the study is to assess the sensitivity and specificity of the LEPTOPLEX multiplex PCR assay at baseline during the acute phase of illness. Secondary outcomes include comparison of detection rates with conventional diagnostic methods assessment of turnaround time agreement with serological reference standard and gene wise positivity pattern.

The study is expected to generate evidence on the utility of LEPTOPLEX as a rapid and reliable diagnostic tool for early detection of leptospirosis and to support its potential use in endemic settings for improved case management and disease control

 
Close